Feb. 16, 2010 -- Women who take combined hormone therapy for just a few years around the time of menopause appear to have no decrease in heart disease risk, new research suggests. If anything, their risk may go up slightly.
The analysis of data from the study that first linked hormone therapy to heart disease found that even in the first two years of use, treatment with estrogen plus progestin was associated with a small, but not statistically significant increase in heart risk when started within 10 years of menopause.
The number of menopausal women in the study who had heart attacks and strokes was quite small, however, and experts say the advice to those contemplating hormone therapy for the relief of hot flashes and other menopausal symptoms remains unchanged.
“Our findings are consistent with the current guidelines to use hormone therapy in the smallest doses for the shortest possible time for symptoms only,” lead researcher Sengwee Toh, ScD, of Harvard Medical School tells WebMD. “We found no evidence of a protective benefit in the early years of use.”
It is now well known that taking combined hormone therapy for many years is associated with an increased risk for heart attacks and strokes in older women who are well past menopause.
But it has not been clear if this risk extends to women who take hormones for just a few years around the time of menopause.
Some studies even suggest that short-term hormone therapy may actually be protective against heart disease in younger women.
In an effort to better understand the impact of combined hormone treatment on heart disease risk around the time of menopause, Toh and colleagues examined data from the widely publicized hormone therapy intervention trial known as the Women’s Health Initiative (WHI).
The WHI included more than 16,000 women, half of whom were randomized to receive combined estrogen plus progestin hormone therapy between 1993 and 1998. The other half of the group received placebos. In 2002, the hormone therapy arm of the trial was suspended because of increased rates of heart disease, breast cancer, and blood clots. Toh and colleagues looked more closely at the data to see if outcomes were influenced by the time span between menopause onset and start of hormone therapy.